TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7655204

Group type: EXPERIMENTAL
Intervention: Mepivacaine 2% (4 ml)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Prilocaine 2% (4 ml)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (4 ml)
Number of subjects: 34
Study: 2698273

Group type: EXPERIMENTAL
Intervention: Amineptine 200 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1099948

Group type: EXPERIMENTAL
Intervention: Inhaled atropine sulfate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inhaled isoproterenol hydrochloride
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31003683

Group type: EXPERIMENTAL
Intervention: One massage per week for two weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Three massages per week for two weeks
Number of subjects: 38
Study: 28704487

Group type: EXPERIMENTAL
Intervention: PRETmax
Number of subjects: 20

Group type: COMPARATOR
Intervention: RAMP
Number of subjects: 20

Group type: COMPARATOR
Intervention: PRETmax vs RAMP
Number of subjects: 20
Study: 26351969

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride, 50 to 100 mg/d
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 23432534

Group type: EXPERIMENTAL
Intervention: Netazepide (1, 5, 25, and 100 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Netazepide (100 mg) twice daily for 13 doses
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21292928

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 160
Study: 19922726

Group type: EXPERIMENTAL
Intervention: N-A (non-adherent, knitted, viscose filament gauze)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Inadine (iodine-impregnated dressing)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Aquacel (newer product)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Non-adherent dressings
Number of subjects: 229

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 229
Study: 16447938

Group type: EXPERIMENTAL
Intervention: Autologous serum eye drops
Number of subjects: 27

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 27
Study: 15648125

Group type: EXPERIMENTAL
Intervention: Stress management training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 43
Study: 11737510

Group type: EXPERIMENTAL
Intervention: CHX 0.2% + alcohol (Corsodyl)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CHX 0.12% + alcohol (Perio.Aid)
Number of subjects: 16

Group type: COMPARATOR
Intervention: CHX 0.12% + sodium fluoride 0.05% (Cariax Gingival)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CHX 0.12% + CPC 0.05% (Perio.Aid, new formulation)
Number of subjects: 16
Study: 8989272

Group type: EXPERIMENTAL
Intervention: 1.0 mg ALN daily
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: 2.5 mg ALN daily
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: 5.0 mg ALN daily
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: ALN (1.0, 2.5, or 5.0 mg)
Number of subjects: 359
Study: 8500697

Group type: COMPARATOR
Intervention: Sham feeding (without intubation)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham feeding (with intubation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral meals
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gastric emptying of solids
Number of subjects: 8
Study: 3303293

Group type: EXPERIMENTAL
Intervention: Sucralfate (Andapsin 1g X 4)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Cimetidine (Tagamet 400mg X 2)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Both interventions (Sucralfate and Cimetidine)
Number of subjects: 371
Study: 29775553

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) administered in one upper quadrant (wavelength: 660 nm; Power: 100 mW; Power density: 100 mW/cm2; Energy density per application point = 2 J/cm2; Total dose = 52 J/cm2; Irradiation time: 26 × 20 sec)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Simulated laser application (control)
Number of subjects: 13
Study: 27178897

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target SBP <140 mm Hg)
Number of subjects: 3184

Group type: COMPARATOR
Intervention: Guideline-based blood pressure management (SBP <180 mm Hg)
Number of subjects: 3184

Group type: EXPERIMENTAL
Intervention: Antithrombotic-associated ICH
Number of subjects: 3184

Group type: EXPERIMENTAL
Intervention: Follow-up CT after 24 hours
Number of subjects: 3184
Study: 24517720

Group type: COMPARATOR
Intervention: Intravaginal progesterone gel (Crinone 8% gel)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Intravaginal progesterone plus oral 2 mg estradiol hemihydrate (E2)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Intravaginal progesterone plus oral 6 mg estradiol hemihydrate (E2)
Number of subjects: 95
Study: 22470429

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study: 21103404

Group type: EXPERIMENTAL
Intervention: Treadmill exercise testing
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Constant work rate tests at 61 ± 33 watts
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Second constant work rate test
Number of subjects: 519
Study: 18502362

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 14758215

Group type: EXPERIMENTAL
Intervention: Synthesis method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open palm technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 11700410

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 15 mg/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate (TM) 10 mg/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 39
Study: 9152745

Group type: EXPERIMENTAL
Intervention: 60 min aerobic exercise at 50% VO2 max with a low-fat diet (mean FO = 0.89)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Rest with a mixed diet (mean FQ = 0.85)
Number of subjects: 6
Study: 7697692

Group type: EXPERIMENTAL
Intervention: Insulin-glipizide (5 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Insulin-placebo
Number of subjects: 70
Study: 3316301

Group type: EXPERIMENTAL
Intervention: Tiapamil 300 to 600 mg bid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 to 50 mg bid
Number of subjects: 30
Study: 31223150

Group type: EXPERIMENTAL
Intervention: In-class quiz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practicum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trading Places exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cultural competency curriculum elements (practicum, lecture, Worlds Apart videos)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall teaching methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grades improvement
Number of subjects: 0
Study: 29731633

Group type: EXPERIMENTAL
Intervention: Once-monthly paliperidone palmitate initiated </=1 week after hospitalization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once-monthly paliperidone palmitate initiated >1 week after hospitalization
Number of subjects: 0
Study: 26847169

Group type: EXPERIMENTAL
Intervention: Platform switching
Number of subjects: 63

Group type: COMPARATOR
Intervention: Platform matching
Number of subjects: 63

Group type: COMPARATOR
Intervention: Comparison between platform switching and platform matching
Number of subjects: 63
Study: 24514085

Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 251
Study: 22997786

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (suspended moxibustion applied to Yanglingquan for 15 min, massage device used on pain area, self-help or mutual-aid treatment)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Plaster application (Goupi Gao applied to local pain area, treatment once daily for 5 days)
Number of subjects: 58
Study: 20129478

Group type: EXPERIMENTAL
Intervention: Proactive telephone breastfeeding support (2 weeks of daily calls by nurses)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Proactive telephone breastfeeding support
Number of subjects: 341

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 341
Study: 17534702

Group type: EXPERIMENTAL
Intervention: Short-form FCE
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard FCE
Number of subjects: 372
Study: 16337459

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg once daily
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg twice daily
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 11213273

Group type: EXPERIMENTAL
Intervention: Collaborative primary care model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison clinics (control)
Number of subjects: 0
Study: 9429370

Group type: EXPERIMENTAL
Intervention: Experimental groups (specific interventions not detailed)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 8236580

Group type: EXPERIMENTAL
Intervention: Oxytocin injections during the first and second postoperative day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo injections during the first and second postoperative day
Number of subjects: 22
Study: 3655008

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31153628

Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum (TQL) block with ropivacaine 0.75%, 30 ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline 30 ml (control)
Number of subjects: 60
Study: 28939617

Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP<120 mm Hg)
Number of subjects: 13946

Group type: COMPARATOR
Intervention: Conventional treatment (SBP<140 mm Hg)
Number of subjects: 13946
Study: 26759107

Group type: EXPERIMENTAL
Intervention: First line treatment in therapy group
Number of subjects: 405

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 405
Study: 24391801

Group type: EXPERIMENTAL
Intervention: ART with concurrent active TB
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: ART with other non-TB AIDS-defining disease
Number of subjects: 1571

Group type: COMPARATOR
Intervention: ART without concurrent TB or other AIDS-defining disease
Number of subjects: 1571
Study: 21189401

Group type: EXPERIMENTAL
Intervention: benazepril plus amlodipine
Number of subjects: 573

Group type: COMPARATOR
Intervention: benazepril plus hydrochlorothiazide
Number of subjects: 573
Study: 18566886

Group type: EXPERIMENTAL
Intervention: Study Group (SG) - preoperative and postoperative education programs, home visits from outpatient team
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control Group (CG) - conventional rehabilitation, possible stay at rehabilitation center
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Study Group (SG)
Number of subjects: 50
Study: 16580903

Group type: EXPERIMENTAL
Intervention: Midazolam (0.075 mg/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Midazolam and Simvastatin correlation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Midazolam and Simvastatin AUC inhibitory ratio
Number of subjects: 19
Study: 14608317

Group type: EXPERIMENTAL
Intervention: Arthroscopic‐assisted bilateral buttress plate fixation
Number of subjects: 18
Study: 10683436

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 4.2 g/day for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9081102

Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training and incentive spirometry, 1 hour per day, six times a week, for 2 weeks before and 3 months after lung resection (group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No training (group B)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training and incentive spirometry (group A)
Number of subjects: 32
Study: 8147043

Group type: EXPERIMENTAL
Intervention: Modified orthostatic test during pregnancy
Number of subjects: 161
Study: 31718542

Group type: EXPERIMENTAL
Intervention: Multimodal training programme (MTP) with Integrated Brief Systemic Therapy (IBST) approach
Number of subjects: 38

Group type: COMPARATOR
Intervention: Routine clinical Mental health support programme for primary care (Control)
Number of subjects: 38
Study: 29618548

Group type: EXPERIMENTAL
Intervention: Insect-fungus interaction networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wood-decay fungi interactions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plant pathogenic fungi interactions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insect symbiont fungi interactions
Number of subjects: 0
Study: 26921473

Group type: EXPERIMENTAL
Intervention: Bag-valve ventilation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask (LMA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: I-Gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EasyTube
Number of subjects: 30
Study: 24710760

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 22277987

Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol plus cyclical micronized progesterone for 3 months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no hormone therapy)
Number of subjects: 84
Study: 20350191

Group type: EXPERIMENTAL
Intervention: MVA (ACAM3000) administered intradermally at 1 x 10(7) TCID(50)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MVA (ACAM3000) administered intramuscularly or subcutaneously at 1 x 10(8) TCID(50)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 18702944

Group type: EXPERIMENTAL
Intervention: Olive oil rich in oleic acid (18:1n‐9)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sunflower oil rich in linoleic acid (18:2n‐6)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Flaxseed oil rich in linolenic acid (18:3n‐3)
Number of subjects: 15
Study: 15945400

Group type: EXPERIMENTAL
Intervention: promethazine 25 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: meclizine 50 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: dimenhydrinate 50 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: promethazine 25 mg plus pseudoephedrine 60 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: promethazine 25 mg plus d‐amphetamine 10 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 12841887

Group type: COMPARATOR
Intervention: Levormeloxifene (four different doses) for 12 months
Number of subjects: 381

Group type: COMPARATOR
Intervention: Raloxifene (three different doses) for 24 months
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo for both studies
Number of subjects: 381
Study: 10597781

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 100
Study: 8598506

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: COMPARATOR
Intervention: Hawthorne effect
Number of subjects: 180

Group type: COMPARATOR
Intervention: Natural history
Number of subjects: 180
Study: 1745622

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen 2000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg plus codeine phosphate 60 mg (APAPCOD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study: 6285814

Group type: EXPERIMENTAL
Intervention: Ketoconazole after fasting (200 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketoconazole after standardized meal (660 kilocalories) (brand 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketoconazole with orange juice (300 ml) (brand 1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Miconazole after fasting (250 mg)
Number of subjects: 10
Study: 30376391

Group type: EXPERIMENTAL
Intervention: Quartile 2 of HEI‐2010 score
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Quartile 3 of HEI‐2010 score
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Quartile 4 of HEI‐2010 score
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Quartiles 2, 3, and 4 of HEI‐2010 score
Number of subjects: 1220
Study: 28671000

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 50
Study: 25644619

Group type: EXPERIMENTAL
Intervention: Clear lens extraction by phacoemulsification
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 50
Study: 24499492

Group type: EXPERIMENTAL
Intervention: 5 mg NRL001
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 10 mg NRL001
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 15 mg NRL001
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1 g suppository (NRL001)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2 g suppository (NRL001)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NRL001 (up to 15 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NRL001
Number of subjects: 26
Study: 21791543

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention to optimize pharmacological therapy
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1092
Study: 19402341

Group type: COMPARATOR
Intervention: Commercial tablets (COM) 150 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Magistral suspension (MAG) 150 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Magistral suspension (MAG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both treatments (COM and MAG)
Number of subjects: 16
Study: 15081450

Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy before direct infarct artery stenting
Number of subjects: 100

Group type: COMPARATOR
Intervention: Direct infarct artery stenting alone (placebo group)
Number of subjects: 100
Study: 11845943

Group type: EXPERIMENTAL
Intervention: adapalene gel 0.1%
Number of subjects: 168

Group type: COMPARATOR
Intervention: tretinoin microsphere gel 0.1%
Number of subjects: 168
Study: 9576145

Group type: EXPERIMENTAL
Intervention: Atopic T-cell lines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonatopic T-cell lines
Number of subjects: 0
Study: 7820040

Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Alpha interferon (aIF)
Number of subjects: 90
Study: 3289524

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 12
Study: 29848361

Group type: EXPERIMENTAL
Intervention: Febuxostat XR 40 mg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Febuxostat IR 40 mg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Febuxostat IR 80 mg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Febuxostat XR 80 mg
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 28196003

Group type: EXPERIMENTAL
Intervention: Bictegravir (BIC) 5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bictegravir (BIC) 25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bictegravir (BIC) 50 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bictegravir (BIC) 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25717011

Group type: EXPERIMENTAL
Intervention: Assisted Living (DAL) residents with dementia
Number of subjects: 609

Group type: COMPARATOR
Intervention: Long-Term Care (LTC) residents with dementia
Number of subjects: 609
Study: 24617242

Group type: COMPARATOR
Intervention: Routine drug anesthesia (group A)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Meridian point 2 Hz (group B)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Meridian point 2 Hz/100 Hz (group C)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Meridian point 100 Hz (group D)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electric stimulation 2 Hz/100 Hz (group E)
Number of subjects: 124
Study: 21266337

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 47
Study: 17375114

Group type: EXPERIMENTAL
Intervention: Low-energy parenteral nutrition without amino acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-energy parenteral nutrition containing amino acids (two types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete parenteral nutrition
Number of subjects: 0
Study: 16533223

Group type: EXPERIMENTAL
Intervention: Maintenance narrow-band UVB therapy for 2 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Maintenance narrow-band UVB therapy for plaque-type psoriasis
Number of subjects: 50

Group type: COMPARATOR
Intervention: No maintenance therapy for plaque-type psoriasis
Number of subjects: 50
Study: 12933413

Group type: EXPERIMENTAL
Intervention: Ketamine (Group K)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (Group M)
Number of subjects: 93
Study: 10643851

Group type: EXPERIMENTAL
Intervention: 5 million units/m2 body surface area of recombinant interferon alpha 2b (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 million units/m2 body surface area of recombinant interferon alpha 2b (Group II)
Number of subjects: 30
Study: 8880107

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 100 micrograms b.d.
Number of subjects: 190

Group type: COMPARATOR
Intervention: Inhaled salbutamol 400 micrograms q.d.s.
Number of subjects: 190